103343-66-4

Basic information

• Product Name: (R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE
• Synonyms: (R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE;2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-methyl-5-phenyl-, (3S)-
• CAS NO: 103343-66-4
• Molecular Formula: C₁₆H₁₅N₃O
• Molecular Weight: 265.3098
• Mol File: 103343-66-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE(103343-66-4)
• EPA Substance Registry System: (R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE(103343-66-4)

Safety Data

• Hazardous Substances Data: 103343-66-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE is used as a potential therapeutic agent for the treatment of anxiety, insomnia, and seizure disorders due to its benzodiazepine nature and associated properties.
Used in Research and Development:
(R)-3-AMINO-1-METHYL-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE is also utilized in research and development settings to study its pharmacological effects, stereochemistry, and the possibility of its application in the development of new drugs with improved efficacy and safety profiles.

Upstream product

• 103421-61-0 3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
• 108896-03-3 (R)-2-Amino-N-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide 
• 103343-63-1 3(S)-(2(S)-amino-3-phenylpropanoylamino)-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 103373-62-2 1,3-dihydro-1-methyl-3-oximido-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 2898-08-0 2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one 
• 3034-65-9 1-methyl-2,3-dihydro-2-oxo-5-phenyl-1,4-benzodiazepine 
• 108895-98-3 benzyl 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamate 
• 108895-97-2 2-α-(benzyloxycarbonyl)glycinyl)amino>benzophenone 
• 103343-47-1 3-amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 
• 207600-11-1 [(S)-1-(1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 207600-12-2 [1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)-2-phenylethyl] carbamic acid tert-butyl ester 
• 103343-61-9 [(R)-1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 103343-62-0 1,1-dimethylethyl<(R)-2-<(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino>-2-oxo-1-(phenylmethyl)ethyl>carbamate 

Downstream Products

• 116842-78-5 4-Methyl-pentanoic acid ((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide 
• 108896-04-4 (3S)-(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-iodobenzenecarboxamide 
• 116842-94-5 N-((S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-pentyl-benzamide 
• 118101-09-0 1-((S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea 
• 103421-59-6 2-Chloro-N-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide 
• 116842-95-6 (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(trifluoromethyl)-benzamide 
• 116842-77-4 (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methylpropanamide 
• 116842-79-6 (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-cyclohexanecarboxamide 
• 146373-97-9 5-Cyclohexyl-1,3-dihydro-1-methyl-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-benzodiazepin-2-one 
• 253136-00-4 3-(benzyloxycarbonyl)-amino-2,3-dihydro-1-methyl-5-phenyl-1H-1-benzazepin-2-one 
• 1401067-34-2 (2S,3R)-6,6,6-trifluoro-3-((⁽³⁵⁾-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 1401066-79-2 (2R,3S)-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3- trifluoropropyl)succinamide 
• 1401067-05-7 tert-butyl (2S,3R)-6,6,6-trifluoro-3-(((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 
• 1401067-06-8 tert-butyl (2R,3R)-6,6,6-trifluoro-3-((⁽³⁵⁾-1-methyl-2-oxo-5-phenyl2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 

Relevant articles and documents

Discovery of clinical candidate BMS-906024: A potent pan-notch inhibitor for the treatment of leukemia and solid tumors

Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in

PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I) and salts thereof, wherein: a) R1 is H or CH3, and R2 is Ry; or b) R1 is Rx and R2 is H; wherein Rx and Ry are disclosed herein.

BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I) or prodrugs thereof; wherein: R1 is —CH2CF3 or —CH2CH2CF3; R2 is —CH2CF3, —CH2CH2CF3, or —CH2CH2CH2CF3; R3 is H or —CH3; each Ra is independently F, Cl, —CN, —OCH3, and/or —NHCH2CH2OCH3; and z is zero, 1, or 2. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

Induced association of μ opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands

Both μ-opioid (MOP) and type 2 cholecystokinin (CCK2) receptors are present in areas of the central nervous system that are involved in modulation of pain processing. We conducted bioluminescence resonance energy transfer (BRET) studies on COS

Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and Type 2 cholecystokinin receptors

Radiolabeled antagonists of specific peptide receptors identify a higher number of receptor binding sites than agonists and may thus be preferable for in vivo tumor targeting. In this study, two novel radioiodinated1,4- benzodiazepines, (S)-1-(3-iodopheny

5-PHENYL-LH-BENZ0 [E] [1, 4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS

Novel hydroxamate histone deacetylase inhibitors of formula (I) wherein X is C=O or CH2 used as antineoplastic agent.

Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones

Two efficient synthetic routes to the 3-amino-1,4-benzodiazepin-2-ones 2 and 3 were developed.The first sequence was carried out in 55-60percent overall yield and involves a novel mercuric ion assisted ammonia displacement of the (alkylthio)glycinamide 14 to produce the key intermediate α-aminoglycinamide 15.The second approach features a practical two-step amination of the parent 1,4-benzodiazepine ring system 24 to afford the title compound 3 in 49percent overall yield from 2-aminobenzophenone.The 3-amino-1,4-benzodiazepine 3 was resolved via the separation of the corresponding diastereomeric phenylalanyl amides.The desired (-)-3 enantiomer was then liberated by use of the Edman degradation.

A NEW AMINE RESOLUTION METHOD AND ITS APPLICATION TO 3-AMINOBENZODIAZEPINES

A new method for the resolution of amines and its application to 3-aminobenzodiazepines 1 is described.The method involves the synthesis and separation of a pair of phenylalanyl amide diastereomers followed by removal of phenylalanine via the Edman degrad